Sino Biopharmaceutical (HKG:1177) secured a supply deal for GlaxoSmithKline's hepatitis B drug, bepirovirsen, for China, according to a Monday filing with the Hong Kong bourse.
The firm's Chia Tai Tianqing Pharmaceutical Group entered into an exclusive strategic collaboration with GSK to cover the importation and distribution of bepirovirsen in mainland China for an initial term of 5.5 years at launch.
Sino Biopharmaceutical's shares were up nearly 2% in midday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.